See more : Paik Kwang Industrial Co., Ltd. (001340.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Inozyme Pharma, Inc. (INZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inozyme Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hokuryo Co., Ltd. (1384.T) Income Statement Analysis – Financial Results
- West Red Lake Gold Mines Inc. (RLGMF) Income Statement Analysis – Financial Results
- ImmunityBio, Inc. (IBRX) Income Statement Analysis – Financial Results
- Jiangsu Recbio Technology Co., Ltd. (2179.HK) Income Statement Analysis – Financial Results
- Ashoka WhiteOak Emerging Markets Ord (AWEM.L) Income Statement Analysis – Financial Results
Inozyme Pharma, Inc. (INZY)
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.29M | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| Gross Profit | -1.29M | -1.18M | -1.05M | -217.00K | -83.00K | -26.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.85M | 47.85M | 37.72M | 46.49M | 16.22M | 8.10M |
| General & Administrative | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Other Expenses | 0.00 | -319.00K | -189.00K | 247.00K | -24.00K | 4.35M |
| Operating Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Cost & Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Interest Income | 7.84M | 1.93M | 211.00K | 370.00K | 1.11M | 284.00K |
| Interest Expense | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 833.00K | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| EBITDA | -74.81M | -65.88M | -55.97M | -56.82M | -20.72M | -11.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -75.65M | -68.68M | -56.65M | -57.04M | -20.81M | -11.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.48M | 1.61M | 22.00K | 617.00K | 1.08M | 4.63M |
| Income Before Tax | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.61M | -211.00K | -587.00K | -1.11M | 4.63M |
| Net Income | -71.17M | -65.45M | -56.41M | -55.84M | -18.62M | -6.96M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EPS Diluted | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| Weighted Avg Shares Out | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
| Weighted Avg Shares Out (Dil) | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial...
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present...
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency...
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY
NEW YORK , Aug. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such investors are advised to contact Robert S.
Top Penny Stocks To Buy? 4 To Watch Under $5
Penny stocks are shares of companies trading for under $5. They generally are the stock of companies in early or development stages that are typically smaller in size.
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 –
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY
NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such investors are advised to contact Robert S.
Source: https://incomestatements.info
Category: Stock Reports